These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 24897088)

  • 1. Pharmacology and the treatment of complicated skin and skin-structure infections.
    Chambers HF
    N Engl J Med; 2014 Jun; 370(23):2238-9. PubMed ID: 24897088
    [No Abstract]   [Full Text] [Related]  

  • 2. Dalbavancin or oritavancin for skin infections.
    Corey GR; Jiang H; Moeck G
    N Engl J Med; 2014 Sep; 371(12):1162-3. PubMed ID: 25243251
    [No Abstract]   [Full Text] [Related]  

  • 3. Dalbavancin or oritavancin for skin infections.
    Baang J; Fisher S
    N Engl J Med; 2014 Sep; 371(12):1160-1. PubMed ID: 25229924
    [No Abstract]   [Full Text] [Related]  

  • 4. Dalbavancin or oritavancin for skin infections.
    Núñez-Núñez M; Rodríguez-Baño J
    N Engl J Med; 2014 Sep; 371(12):1160. PubMed ID: 25229923
    [No Abstract]   [Full Text] [Related]  

  • 5. Dalbavancin or oritavancin for skin infections.
    Boucher HW; Talbot GH; Dunne MW
    N Engl J Med; 2014 Sep; 371(12):1161-2. PubMed ID: 25229922
    [No Abstract]   [Full Text] [Related]  

  • 6. Dalbavancin or oritavancin for skin infections.
    Cormican M
    N Engl J Med; 2014 Sep; 371(12):1161. PubMed ID: 25229925
    [No Abstract]   [Full Text] [Related]  

  • 7. Weekly dalbavancin was noninferior to daily vancomycin for acute bacterial skin infection in adults.
    Zervou FN; Zacharioudakis IM; Mylonakis E
    Ann Intern Med; 2014 Oct; 161(8):JC9. PubMed ID: 25329226
    [No Abstract]   [Full Text] [Related]  

  • 8. Reply to DiNubile.
    Corey GR; Boucher HW; Stryjewski ME
    Clin Infect Dis; 2015 Apr; 60(8):1291-2. PubMed ID: 25609681
    [No Abstract]   [Full Text] [Related]  

  • 9. Trials and tribulations of noninferiority: caveat emptor.
    DiNubile MJ
    Clin Infect Dis; 2015 Apr; 60(8):1290-1. PubMed ID: 25609683
    [No Abstract]   [Full Text] [Related]  

  • 10. Dalbavancin and Oritavancin: An Innovative Approach to the Treatment of Gram-Positive Infections.
    Roberts KD; Sulaiman RM; Rybak MJ
    Pharmacotherapy; 2015 Oct; 35(10):935-48. PubMed ID: 26497480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two new drugs for skin and skin structure infections.
    Med Lett Drugs Ther; 2014 Aug; 56(1449):73-5. PubMed ID: 25118799
    [No Abstract]   [Full Text] [Related]  

  • 12. Once-weekly dalbavancin versus daily conventional therapy for skin infection.
    Boucher HW; Wilcox M; Talbot GH; Puttagunta S; Das AF; Dunne MW
    N Engl J Med; 2014 Jun; 370(23):2169-79. PubMed ID: 24897082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dalbavancin (Dalvance) for the treatment of acute bacterial skin infection.
    Gupta AK; Foley KA; Abramovits W; Rosen T
    Skinmed; 2014; 12(6):366-9. PubMed ID: 25823083
    [No Abstract]   [Full Text] [Related]  

  • 14. Single-dose oritavancin in the treatment of acute bacterial skin infections.
    Corey GR; Kabler H; Mehra P; Gupta S; Overcash JS; Porwal A; Giordano P; Lucasti C; Perez A; Good S; Jiang H; Moeck G; O'Riordan W;
    N Engl J Med; 2014 Jun; 370(23):2180-90. PubMed ID: 24897083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic drug evaluation of dalbavancin for the treatment of skin infections.
    Galluzzo M; D'Adamio S; Bianchi L; Talamonti M
    Expert Opin Drug Metab Toxicol; 2018 Feb; 14(2):197-206. PubMed ID: 29258361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oritavancin (Orbactiv) for skin and skin structure infections.
    Med Lett Drugs Ther; 2015 Jan; 57(1459):3-5. PubMed ID: 25555072
    [No Abstract]   [Full Text] [Related]  

  • 17. Use of vancomycin as a surrogate for dalbavancin in vitro susceptibility testing: results from the DISCOVER studies.
    Dunne MW; Sahm D; Puttagunta S
    Ann Clin Microbiol Antimicrob; 2015 Apr; 14():19. PubMed ID: 25885674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New Gram Positive Agents to Treat Acute Bacterial Skin and Skin Structure Infections.
    Li R; Nailor MD
    Conn Med; 2016 Mar; 80(3):175-80. PubMed ID: 27169303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dalbavancin and telavancin: novel lipoglycopeptides for the treatment of Gram-positive infections.
    Zhanel GG; Trapp S; Gin AS; DeCorby M; Lagacé-Wiens PR; Rubinstein E; Hoban DJ; Karlowsky JA
    Expert Rev Anti Infect Ther; 2008 Feb; 6(1):67-81. PubMed ID: 18251665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New antibiotics in the management of acute bacterial skin and skin structure infections.
    Gleghorn K; Grimshaw E; Kelly EK
    Skin Therapy Lett; 2015; 20(5):7-9. PubMed ID: 26382907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.